Fund Holdings — GILEAD SCIENCES, INC.

Total Portfolio Value
$2.12B
Total Bought
$0
Total Sold
$359.5K
Net Transaction
-$359.5K
Filing Period:
Securities
▲▼
SharesValue ($K)
Q4 2025
▲▼
Q1 2026
▲▼
Change
▲▼
Q4 2025
▲▼
Q1 2026
▲▼
Weight (%)
▲▼
Change
▲▼
Arcellx Inc
COMMON STOCK
6,720,8036,720,8030438,196771,68336.44%+333,486
Xilio Therapeutics Inc(XLO)9,105,451650,389-8,455,0625,8295,4700.26%-360
Kyverna Therapeutics Inc(KYTX)4,126,1194,126,119038,78635,6081.68%-3,177
Assembly Biosciences Inc4,505,3914,505,3910153,228125,0255.90%-28,204
Galapagos NV(LKFT)16,707,47716,707,4770550,616501,22423.67%-49,392
Arcus Biosciences Inc(RCUS)31,424,76031,424,7600748,852678,77532.05%-70,077
Page 1 of 1
GILEAD SCIENCES, INC. — 13F Holdings — Q1 2026 | TickerTrail